NCT05247385

Platelet Aggregation and Adenosine Levels Among Patients Taking Ticagrelor or Prasugrel

Platelet Aggregation and Adenosine Levels Among Patients With Stable Chronic Coronary Artery Disease Taking Ticagrelor or Prasugrel

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 87 (actual)
• Sponsor: University of Sao Paulo · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

Prospective, single-center, double blind, double dummy, randomized trial. Platelet function tests and adenosine levels were assessed at baseline and 15 days after taking Ticagrelor with Prasugrel placebo or Prasugrel with Ticagrelor placebo in stable patients with coronary artery disease

Detailed description

This was a prospective, double blinded, randomized trial that compared platelet inhibition and adenosine levels with ticagrelor (180mg loading dose, followed by 90 mg BID) versus prasugrel (60mg loading dose, followed by 10 mg QD) . Patients were eligible if they were between 18 and 75 years old, were on aspirin without P2Y12 inhibitor at baseline and \> 1 year after documented ACS. Platelet aggregation was compared with the Multiplate ADP® assay, performed at baseline and after 15 days on study medication. Adenosine plasma levels were measured with high performance liquid chromatography at the same time points

Conditions

• Coronary Artery Disease

Interventions

Type	Name	Description
DRUG	Prasugrel	Compared platelet inhibition and adenosine levels at baseline and after 15 days
DRUG	Ticagrelor	Compared platelet inhibition and adenosine levels at baseline and after 15 days

Timeline

• Start date: 2017-03-20
• Primary completion: 2021-02-26
• Completion: 2021-12-20
• First posted: 2022-02-18
• Last updated: 2022-02-18

Locations

1 site across 1 country: Brazil